|
|
 |
|
Viewing report
|
|
|
|
Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review
GlobalData, March 2012, Pages: 39
Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review
Summary
Avanir Pharmaceuticals, Inc. (Avanir) is a biopharmaceutical company engaged in acquisition, development and commercialization of novel therapeutic products for chronic diseases targeted on the treatment of central nervous system (CNS) disorders. The company has one commercialized drug which is Nuedexta developed for the treatment of pseudobulbar affect (PBA). The pipeline portfolio offered by the company includes AVP-923 which is in Phase-II and III clinical trials for the treatment of Multiple Sclerosis Pain and diabetic neuropathic pain. Avanir manufactures and sells these products through third party sources. The company has all its operations based in the US. Avanir is headquartered in California, the US.
The company focuses on successful development of its product pipeline as well expanding its current market for PBA. This is reflected from the recent filing of IND (investigational new drug) application for AVP-923 with the US Food and Drug Administration (FDA), and acceptance of marketing authorization for Nuedexta in Europe by the European Medicines Agency.
Avanir Pharmaceuticals, Inc. Key Recent Developments
Feb 07, 2012: AVANIR Pharmaceuticals Reports Net Revenue Of $7.2m In Q1 Fiscal 2012
Dec 13, 2011: AVANIR Pharmaceuticals Reports $6.1m In Fiscal 2011
Oct 12, 2011: Avanir Pharmaceuticals To Present Data At American Congress of Rehabilitation Medicine/American Society For Neurorehabilitation Medicine Annual Conference
Aug 31, 2011: Impax Confirms Patent Challenge Relating To Generic NUEDEXTA 20mg/10mg
Aug 11, 2011: Avanir Files Lawsuits Against Par And Actavis For Infringement Of NUEDEXTA Patents
This comprehensive SWOT profile of Avanir Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Key Words
Avanir Pharmaceuticals, Inc., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History, Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Customers who bought this item also bought
AnGes MG, Inc. (4563) - Financial and Strategic SWOT Analysis Review
Alexza Pharmaceuticals, Inc. (ALXA) - Financial and Strategic SWOT Analysis Review
Par Pharmaceutical Companies, Inc. (PRX) - Financial and Strategic SWOT Analysis Review
Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review
Hospira, Inc. (HSP) - Financial and Strategic SWOT Analysis Review
GlaxoSmithKline plc (GSK) - Financial and Strategic SWOT Analysis Review
Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT Analysis Review
Transdel Pharmaceuticals, Inc. (TDLPD) - Financial and Strategic SWOT Analysis Review
Mitsubishi Tanabe Pharma Corporation (4508) - Financial and Strategic SWOT Analysis Review
NPS Pharmaceuticals, Inc. (NPSP) - Financial and Strategic SWOT Analysis Review
|
|
|
|
